The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents ?

Authors: Lambert D.M.; Vandevoorde S.; Jonsson K-O.; Fowler C.J.

Source: Current Medicinal Chemistry, Volume 9, Number 6, March 2002 , pp. 663-674(12)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

The discovery of anandamide as an endogenous ligand for the cannabinoid receptors has led to a resurgence of interest in the fatty acid amides. However, N-palmitoylethanolamine (PEA), a shorter and fully saturated analogue of anandamide, has been known since the fifties. This endogenous compound is a member of the N-acylethanolamines, found in most mammalian tissues. PEA is accumulated during inflam-mation and has been demonstrated to have a number of anti-inflammatory effects, including beneficial effects in clinically relevant animal models of inflammatory pain. It is now engaged in phase II clinical development, and two studies regarding the treatment of chronic lumbosciatalgia and multiple sclerosis are in progress. However, its precise mechanism of action remains debated. In the present review, the biochemical and pharmacological properties of PEA are discussed, in particular with respect to its analgesic and anti-inflammatory properties.

Keywords: Palmitoylethanolamide; anandamide; cannabinoid; N-acylethanolamines; dicyclohexylcarbodiimide; N-palmitoylethanolamine; N-oleoylethanolamine; Tetrahydrocannabinol; Amide Hydrolase

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/0929867023370707

Publication date: 2002-03-01

More about this publication?

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.